Core Viewpoint - On February 3, 2026, the company announced that it received the Clinical Trial Approval Notification from the National Medical Products Administration for its drug, Recombinant Exendin-4-Fc Fusion Protein Injection [2] Group 1 - The approval notification number is 2026LP00310 [2] - The drug is intended for clinical trials, indicating progress in the company's research and development efforts [2]

Core Viewpoint - The announcement indicates that Hualan Biological has received approval from the National Medical Products Administration for clinical trials of its recombinant Exendin-4-Fc fusion protein injection (HL08) for use in overweight or obese adults, expanding its application beyond type 2 diabetes management [1] Group 1 - Hualan Biological's HL08 has been approved for clinical trials to improve weight control in obese patients, in addition to its original indication for blood sugar control in type 2 diabetes patients [1] - The approval allows the company to officially conduct clinical research to further verify the safety and efficacy of HL08, laying the groundwork for future registration and market launch [1] - This new indication enhances the company's biopharmaceutical product pipeline and optimizes its product structure [1]

Group 1 - The company, Recbio, announced that as of January 31, 2026, it has repurchased a total of 904,054 shares through a dedicated securities account for share buybacks, representing 0.98% of its total share capital of 92,707,940 shares [1]

·韩国保健产业振兴院（KHIDI）预测显示，2026年韩国生物健康产业规模将达2900亿美元，同比增长 20.8%，创2019年以来最高增速。该机构指出，化妆品、药品和医疗器械出口强劲是主要驱动力。全球 生物健康产业规模2026年将达15.77万亿美元，同比增长6.2%；而韩国产业占比持续提升，出口额有望 达304亿美元，其中化妆品（125亿美元）和药品（117亿美元）贡献最大。 ·NLI研究所：日元疲软或触发美债市场连锁反应 ·Domain：澳储行意外加息25基点，旨在遏制房价过热 ·汇丰银行：AI热潮推高信用债估值，市场脆弱性上升 ·SMBC：美国银行准备金逼近3万亿美元，实质性缩表"在操作上不可行" 【机构分析】 ·Elara Securities经济学家指出，美印贸易协议有望显著提振印度经济。预计美国下调关税将推动印度名 义GDP同比增速提高0.4个百分点。如果未来欧盟自贸协定全面生效，中期内印度名义GDP增速将额外 提高。美印贸易协议将改善印度国际收支状况，2027财年经常账户逆差有望收窄。预计未来几周卢比兑 美元汇率或走强。 ·汇丰银行策略师表示，信用债市场对人工智能（AI）的过度乐观已推高资产价 ...

香港联交所最新资料显示，1月28日，摩根大通增持信达生物(01801)19.8871万股，每股作价83.829港 元，总金额约为1667.12万港元。增持后最新持股数目约为8678.41万股，最新持股比例为5%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月28日，摩根大通增持信达生物(01801)19.8871万股， 每股作价83.829港元，总金额约为1667.12万港元。增持后最新持股数目约为8678.41万股，最新持股比 例为5%。 ...

Group 1 - The company has changed its English name from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited" and its Chinese name from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司," effective from December 30, 2025 [1] - The change in company name has been approved by shareholders at a special meeting and certified by the Registrar of Companies in the Cayman Islands [1] - The new names have been registered in Hong Kong under the Companies Ordinance, confirming the new English and Chinese names [1] Group 2 - The company's stock trading name on the Hong Kong Stock Exchange will change from "GENOR" to "EDDING GENOR," and the Chinese stock name will change from "嘉和生物" to "亿腾嘉和," effective from February 6, 2026 [2] - The company's stock code on the Hong Kong Stock Exchange will remain "6998" despite the name changes [2] - The name changes aim to align with the expanded business of the group post-merger and better reflect the relationship with the controlling shareholder [2]

Core Viewpoint - The company has successfully changed its name from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited," effective from December 30, 2025, at 9:00 AM Hong Kong time [1]. Group 1 - The special resolution regarding the name change was approved at the shareholders' special meeting [1]. - The company's Chinese name has also been updated from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司" [1]. - The name change is officially recognized by the Registrar of Companies in the Cayman Islands [1].

北京商报讯(记者王寅浩宋雨盈)2月3日，派林生物（000403）发布公告称，公司全资子公司广东双林生 物制药有限公司收到国家药品监督管理局核准签发的静注人免疫球蛋白药品补充申请《受理通知书》， 2.5g/瓶、5g/瓶和10g/瓶的静注人免疫球蛋白的境内生产药品补充申请获受理。 根据公告，静注人免疫球蛋白主要适应症包括原发性免疫球蛋白缺乏症、继发性免疫球蛋白缺陷病以及 自身免疫性疾病。目前国内拥有静注人免疫球蛋白(5g/瓶，10%，50ml)上市批件的企业包括成都蓉生药 业有限责任公司、贵州泰邦生物制品有限公司以及华润博雅生物（300294）制药集团股份有限公司。 ...

Core Viewpoint - The company has entered into a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Company for approximately HKD 40 million to HKD 45 million, which is seen as a strategic investment to enhance its participation in the healthcare sector and create long-term value [1] Group 1: Acquisition Details - The acquisition involves China Gene Engineering Company, which is registered in Hong Kong and holds approximately 67.68% of Shanghai Huaxin Biological High-tech Co., Ltd [1] - The total consideration for the acquisition is estimated to be between HKD 40 million and HKD 45 million [1] Group 2: Business Synergy - China Gene Group is primarily engaged in the internal research and development, manufacturing, and sales of biopharmaceutical products in China [1] - The acquisition aligns with the company's existing businesses in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services [1] Group 3: Strategic Importance - The board views the acquisition as an excellent opportunity to increase the company's involvement in the operations of China Gene Group [1] - This strategic investment is expected to generate potential long-term value and facilitate business development in the promising healthcare industry [1]